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ABSTRACT
Compositions for treating tissue damage from ischemia
contain PBN, or active derivatives thereof, which are

active during ischemia in preventing ATP depletion of
the cells which predisposes them to subsequent injury
during reperfusion, and which are active during reper
fusion as oxygen radical scavengers, in a suitable phar

maceutical carrier for systemic or local administration,
especially to the CNS, spinal column and eyes. Based on
animal studies, the dosage for treating damage due to
stroke is in the range of 10 to 300 mg/kg. Similar dos
ages are useful in treating damage resulting from free
radical generation during in?ammation, either as a
product ofinfection or exposure to inflammatory agents
or abusive agents, including drugs and alcohol.

Novelli et al., Oxygen Free Radicals in Shock, Int. Work

shop, Florence 1985, pp. 119-124 (Karger, Basel 1986).

18 Claims, 5 Drawing Sheets
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autoxidation of many compounds (e.g.. catechola
PHENYL BUTYL NITRONE COMPOSITIONS AND
METHODS FOR TREATMENT OF OXIDATIVE
TISSUE DAMAGE

mines). Several ischemic events favor a spurt of free

radical formation, e.g., those causing oxidation of

polyenoic free fatty acids, release and reuptake of cate
cholamines, and oxidation of hypoxanthine by xanthine

BACKGROUND OF THE INVENTION

oxidase. Although all these events occur during recircu

lation, when the O2 supply is restored, they represent
metabolic cascades triggered by agonist-receptor inter

This is generally in the area of compositions and
methods for use thereof for the treatment of oxidative
tissue damage such as that resulting from ischemia or
in?ammation, wherein the active compounds are

actions, energy failure, and/or calcium influx during the
insult. Although free radical formation is a likely cause

of ischemic damage, it has been difficult to directly

phenyl butylnitrone (PBN) or derivatives thereof.
Oxygenated tissue suffers damage, in many cases
permanent damage, if it becomes ischemic and is then

demonstrate that such formation occurs and/or that it is

sufficiently pronounced to overwhelm the antioxidative

reperfused. Oxygen free radicals have been implicated

defense of the tissue. Curran, et al., M01. Cell. Biol. 5.
in the injury. Brain appears to be uniquely susceptible to 5 167-172 (1985). In recent years, however. evidence has
ischemia/reperfusion injury, and neurons are more sus

been obtained that ischemia may cause conjugated di
enes and malondialdehyde to accumulate in the tissue.

ceptible than glial cells. Certain areas of the brain, for
example, the hippocampus and spinal cord, are more
susceptible than other regions of the brain. As a result,
ischemia/reperfusion injury to brain may have a multi
plicative effect simply because of the necessity for com
plete integrity of all regions in order to have proper

Nonetheless, it remains to be conclusively shown that
' free-radical damage to unsaturated acyl chains in phos
pholipids, to protein. or to nucleic acids constitutes an

important part of the ischemic necrosis. At present. the
evidence is relatively strong for an involvement of free
radical mechanisms in vascular injury. but not for dam

functioning. -

Several mechanisms may cause ischemic brain dam

age. For example, the mechanisms responsible for selec
tive neuronal vulnerability may be different from those
that cause glial swelling and extensive brain edema, and
a third set of events may underlie such gross functional

aberrations as seizures. Siesjo, Critical Care Med. 16,
954-963 (1988), has grouped the numerous observations
into four possible mechanisms to explain the injury in
brain. These include: (A) calcium mediated cell death,

(B) excitotoxic damage (glutamate buildup), (C) free
radical events and (D) acidosis. It is likely that all four
basic mechanisms are either interrelated or contribute

collectively to the injury observed.
It now seems likely that selective neuronal vulnera
bility is, at least to some extent, an excitotoxic lesion

la La

age affecting nerve and glial cells.
Reviews by Hall and Braughler. Free Radical Biol.
Med. 6, 303-313 (1989), Kontos, Physiology ofOxygen
Radicals, ed. Taylor, Matalon and \Vard. pp. 207-216

(Am. Physiol. Soc, Bethesda. MD 1986). and Ernster.
Critical Care Med. 16, 947-953 (1988). document a sig
ni?cant amount of evidence implicating oxidative dam
age in head and spinal cord injury as well as in hemor

rhagic stroke and ischemic stroke. Most research which

strongly implicates the primary role of oxidative dam
age in ischemia/reperfusion injury in brain can be
grouped into either oftwo types ofstudies: those which

show protection by addition of agents preventing

that is triggered by the release of glutamate and/or

peroxidative events, or those designed to observe free
radicals.

aspartate from depolarized nerve endings. At the mem
brane and molecular levels, calcium influx via NMDA

cal use in treating tissue damage due to ischemia. sev

activated channels is probably crucial, although os
molytic damage to dendritic spines and dendrites could
contribute. It has never been satisfactorily explained,

Although no drugs are currently approved for clini

eral compounds have been proposed as potentially
being effective. Mannitol, an osmotic agent and an oxy
gen scavenger. has been added to reperfusion media and

may limit damage to organs for transplantation. Super

however. how ischemia could cause delayed neuronal
death.

oxide dismutase (SOD) has been suggested as a means

The mechanisms that cause laminar necrosis, glial
destruction, and infarction are more speculative. The

ing compounds that interfere with peroxidation genera

inability of the cells to regulate their volume may be
caused by a molecular defect where edema is a conspic

by J. M. McCall. Acta Anesthesia Belgica, First Antwerp

uous feature. Cells that possess coupled antiporters for

Int. Trauma Symp., which have been reported to be
efficacious if given during or after ischemia. For exam

Na+/H+ and Cl—/HCO3 exchange may regulate pHi
at the expense of volume regulation, so that edema may

be coupled to acidosis.

When ischemia is accompanied by a delayed acidosis
related damage, it seems likely that the lowering of pH
causes changes in protein structure and function, which
~‘mature” with time and ultimately cause gross mem
brane dysfunction. It is tempting to assume that the

primary lesion is an iron-catalyzed free-radical damage
to membrane components, enhanced by the drastic

lowering of pHi and/or pHe.
Free radicals have been postulated to be mediators of

reperfusion damage. The important production sites of

for limiting in vivo oxidative damage. The most promis
tion are the lazaroids, modi?ed prednisones, described

ple, Hall, et al, Stroke 19, 997-1002 (1988), demon
strated that the 21-aminosteroid (474006F), which is
known to prevent peroxidation in brain homogenate, as
described by Braughler, et al., J. Biol. Chem. 262.

10438-10440 (1987), protected gerbils against brain
damage induced by three hours of unilateral carotid
artery occlusion. White and Aust and co-workers, Adv.
Free Radical Biol. Med. 1, 1-17 (1985). and Babbs. Re
suscitation 13, 165-173 (1986), have demonstrated that
iron chelators protect animals from ischemia/reperfu~

sion injury.
With regard to direct demonstrations of oxidative

such radicals as the superoxide (Og—) and hydroxyl 65 events during ischemia/reperfusion injury in brain.
there are pertinent observations using spin-trapping
(OH) species are the mitochondrial respiratory chain
techniques. salicylate hydroxylation. protein oxidation.
and the sequences catalyzed by cyclooxygenase and
and nucleic acid oxidative damage. Spin-trapping has
lipoxygenase. However, radicals are also formed furing

5,025,032
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provided clear evidence implicating free radical pro
duction during ischemia/reperfusion injury. Imaizumi,

wherein R is H,

et al, Neurological Res. 8. 214-220 (1986), showed that
the spin-trap PBN when incubated with rat brain ho

mogenate of animals which had experienced very low
oxygen pressure for 5 min was able to trap an appar

ently lipid-type radical. Kirsch, et al, Pediatric Res. 21,
202A (1987), stated in a preliminary note that PBN had
trapped free radicals in post ischemic brains from ani

mals pretreated with the spin-trap. McCay‘s group have

and n is a whole integer from 1 to 5: or
O

spin trapped free radicals in mouse brain, Arch. Bio
c/zem. Biophys. 244, 156-160 (1986), and shown that
spin-trapped free radicals of PBN are present in blood
leaving the heart of intact dogs recovering from a
“stunned“ myocardiurn, J. Clin. Invest. 82, 476-485
(1988). As described, the free radicals spin-trapped are
apparently lipid-type free radicals and appear within 1
min after release of occlusion and reach peak intensity
about 5 min after reperfusion starts. PBN enhanced
recovery of the post ischemic function ofthe “stunned"
heart.

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or
OW

In summary, while PBN has been used in a number of

research studies, there has been no data to support the

proposition that it could be useful in vivo. particularly

II

II

wherein W is C--CH3. NH-C-Z.

with respect to treatment oftissue damage in the central
nervous system. In vivo, the drug must be able to (I)
cross the blood brain barrier and (2) act in a manner

which reduces tissue damage during or following isch
emia.

O

0

II

II

It is therefore an object of the present invention to Lu 0 Z is a C1 to C5 straight or branched alkyl group.

provide composition and methods for use thereof which
are useful in preventing or reversing ischemic damage

Based on animal studies. the dosage for treating dam
age due to stroke is in the range of 10 to 300 mg/kg.

in vivo., especially in the CNS. spinal cord and eyes.

The compositions are administered prior to or during

It is a further object of the present invention to pro

ischemia in an effective dosage to prevent or reverse

vide compositions and methods for use thereof which
are useful in preventing or reversing free radical dam
age in vivo resulting from infection and inflammation.
It is another object of the present invention to pro
vide compositions and methods for use which prevent

predisposition of the cells to damage resulting from
depletion of ATP (as demonstrated by in vivo NMR)
and damage from free radical generation following
reperfusion. The preferred method of administration is

energy depletion of cells during ischemia.

preferred method of administration for treating in?am
mation is by directed delivery to the site of inflamma
tion. Examples of diseases which can be treated include
stroke. meningitis. progressive neuronal loss due to
Parkinson's disease, senile dementia. and drug abuse.
disorders arising from exposure to high pressure oxygen
or enriched oxygen environments, and bleeding into

intravenously in humans for treatment of stroke. The

It is still another object of the present invention to
provide compositions and methods for use which are
useful in the treatment of a variety of disorders in addi
tion to those resulting from ischemia. including progres
sive neuronal loss from disease or drug and alcohol

abuse and disorders resulting from photooxidation and
exposure to high pressure or enriched oxygen.

nervous tissue as a result of trauma.

SUMMARY OF THE INVENTION

Compositions for treating tissue damage from isch
emia contain PBN, or active derivatives thereof. having

the following general formula, in a suitable pharmaceu
tical carrier for intravenous administration.

50

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph of the dose-effect curve for the
beneficial effects of PBN on transient ischemia-induced

hyperactivity, plotting locomotor activity versus PBN
dose in mg/kg. Young adult gerbils were given a single
55 dose of PBN 1 hr. before 5 min of bilateral carotid

H

O“

\
/
C=N__
/
\
X

occlusion. Twenty-four hours later the change in spon
taneous locomotor activity was determined. Control

(con) value represent the level ofexploratory activity of
Y

a group of normal naive gerbils. Saline (Sal) values were

determined in gerbils injected with saline 1 hr. prior to
ischemia. Data presented represent the mean (:SE.)
for 6 gerbils per treatment group.

wherein:
X is phenyl or
(OR)n

FIG. 2 is a graph ofthe effect of PBN on the levels of
activity in successive 10 min intervals for the test de
65 scribed in FIG. 1. Data presented represents the means
(:SE.) for 6 gerbils per treatment group: control

(-O-O-); 32 mg PBN/kg (-A-A) 100 mg PBX/kg
(-[]-[]-); and 300 mg PBN/ltg (-<>-<>—).

5
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FIG. 3 is a graph of the effects of PBN on the post

ing CNS damage following ischemia or inflammation.

ischemic locomotor activity of aged gerbils (greater

As used herein, ischemia is de?ned as a blockage of
blood flow that results in a lesion in the central nervous

than 20 months of age) tested 24 hrs. after a 2 min period
of ischemia, as described in FIG. 1. Control (-O-<>-);

system (CNS), including the spinal column and eyes.
PBN has a number of advantages in the treatment of

saline (-O-O-); and 300 mg PBN/kg (-A-A-).
FIG. 4 is a graph of the effects of administration of
300 mg PBN on 15 min. ischemia-induced changes in

spontaneous locomotor activity of gerbils, plotting lo
comotor activity counts versus time (minutes). Saline
treated group (-O-O-) represents 5 of the 10 control ger
bils (-(>-<>-) tested. The data for PBN (-A-A-) repre
sents all 10 gerbils tested. Control values are for 6 ger
bils. All data are expressed as the mean (:SE). Where
no S.E. is indicated. it is within the dimensions of the
symbol.

.

ischemia induced damage. including being able to pass
through the blood brain barrier and having no measur
able effect on normal or uninjured cells. PBN is the
preferred active compound at this time. although a
number of derivatives are also useful, including hy
droxy derivatives, especially 2-. 3- or 4-hydroxy PBN
and mono-, di- and trihydroxy tert-butyl nitrone: esters.
especially esters which release 2-, 3. or 4-hydroxyphe
nyl t-butyl nitrone such as the acetoxy derivative. 2-. 3-,
15 or 4-carboxyphenyl t-butyl nitrone. such as the ethyl

FIG. 5 is a graph comparing cumulative locomotor
activity counts over successive 10 minute periods for

non-ischemic animals receiving saline (dark

derivative, or phenyl hydroxybutyl nitrone. such as the

acetoxy derivative; alkoxyl derivatives. especially alk
oxyl derivatives which release 2-. or 4-hydroxyphenyl
t-butyl nitrone, such as the methyl derivative; and acet
amide derivatives. especially acetamide derivatives

32 mg

PBN/kg (dark A); 100 mg PBN/kg (.); 300 mg PBN/kg
(dark inverted A); 500 PBN/kg (dark O); 1000 mg
PBN/kg (O); and 2000 mg PBN/kg (inverted A).
FIG. 6 is a bar graph comparing percent survival
after a lethal occlusion of the carotid arteries in gerbils
treated with either saline or 300 mg PEN/kg.

which release 2-, or 4 aminophenyl t-butyl nitrone. such
as the acetyl derivative; diphenyl nitrone (PPN) and the
analogous diphenyl nitrone derivatives. As used herein.
“PBN" refers to both a-phenyl t-butyl nitrone and de

FIG. 7 is a graph comparing the percent carbonyl
protein of control in gerbils that have been subjected to
ischemia. ischemia followed by 15 minutes reperfusion.

agent in the compositions is N-tert-Butyl-a-phenylni

rivatives thereof. unless otherwise stated. The active
trone (PBN) or derivatives thereof that are spin trap
reagents and which also act to prevent ATP depletion

ischemia followed by 60 minutes reperfusion, and isch
emia followed by 60 minutes reperfusion ‘with pre

of cells.

ischemia administration of 300 mg PBN/kg.
FIG. 8 is a graph comparing percent of glutamine
synthase activity of control gerbils that have been sub

The general formula for PBN and useful derivatives
thereof is:

jected to ischemia. ischemia followed by 15 minutes
H

reperfusion. ischemia followed by 60 minutes reperfu
sion, and ischemia followed by 60 minutes reperfusion
with pre-ischemia administration of 300 mg PEN/kg.
FIG. 9 is a graph correlating carbonyl/mg protein
versus glutamine synthetase speci?c activity, control
(-[]- []-); 10 minutes ischemia. no reperfusion (-[in
verted A]-[inverted A]-), 10 minutes ischemia. 15 min
utes reperfusion ([A]-[A]-), 10 minutes ischemia, 60 min
utes reperfusion (-[<>]-[<>]-). and 10 minutes ischemia.
60 minutes reperfusion and PBN (dark []).

O'

/
C=.\'

/
X

\
Y

wherein:
X is phenyl or
(ORm

DETAILED DESCRIPTION OF THE
INVENTION

wherein R is H.

Following ischemia there is a signi?cant increase in
free radical production (both oxygen and carbon cen
tered radicals). The initial damage to brain cells is

thought to result from the peroxidation products with

subsequent damage from secondary (carbon-centered)
radicals. Eventually the metabolic and synthetic path
ways are damaged to such an extent that the cell dies.

PBN and functionally equivalent spin trapping deriva

and n is a whole integer from 1 to 5: or

tives that pass through the blood brain barrier, prevent
cell damage during and subsequent to ischemia by de
creasing or preventing ATP depletion. and still exhibit
spin trapping of oxygen radicals are of bene?t by bond

O

ing to the carbon-centered-free radicals to prevent fur
ther damage by the modi?ed enzyme or other constitu
ent. As used herein, a free radical scavenger or spin trap
reagent is a molecule that will form a stable complex
with a free radical. A free radical carbon trap is a mole
cule in which the free radical is localized on a carbon
atom or a nitrogen atom.

a-phenyl t-butyl nitrone (PBN), and derivatives
thereof. in a pharmaceutical vehicle suitable for intrave
nous administration are useful in preventing or revers

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions: phenyl; or
65

OW
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-continued

ll

8

amples. or intranasally through the pulmonary tract.
The PBN can alternatively be administered locally. by
ll

wherein W is C-CHg. NH-C-Z.

intramuscular or subcutaneous injection. ointment. or

delayed release implant.
Preferred pharmaceutical carriers for intravenous

0

ll

administration are saline or phosphate buffered saline at

C-Cl-b. C-OZ, or Z; and

physiological pH. In the preferred method, PBN is

Z is a C] to C5 straight or branched alkyl group.
The compositions can also contain other active

delivered to the patient intravenously in a dosage in the
range of 10 mg/kg/hr. most preferably in the range of
one to three mg/kg/hr. The dosage can be determined

agents, such as tissue plasminogen activator, streptokirt
ase, or other clot dissolving compounds, other com
pounds which are oxygen radical scavengers such as

mannitol or compounds which prevent peroxidase gen
eration, such as the lazaroids.

Examples demonstrate the utility ofthe compositions
in preventing brain damage and death in animals follow

for the speci?c disease condition and/or species by
conducting measurements, as described in detail below._
In general, an effective dosage is that amount of PBN
that reduces enzyme activity loss by 25%. decreases cell
death by 25%, and/or maintains 25% or more of normal
function.
The present invention will be further understood

ing blockage of blood flow through the carotid artery
to the brain. Exemplary dosages of PBN ranged from 32
to 300 mg/kg of body weight in gerbils. The effective

with reference to the following non-limiting examples
demonstrating methods for determining effectiveness of

range of PBN in humans and other mammals is between

PBN administration for treatment of injury arising from

approximately 10 and 300 mg/kg. The compositions can
be effectively administered prior to, during or after

of the prevention and/or reversal of damage from isch

ischemia. and prevent or decrease the extent of cellular

damage.
The use of compounds which are spin-traps that are

capable of scavenging oxygen radicals during reperfu
sion following ischemia. and which act to block ATP
depletion of the cell (which predisposes the cell to in
jury following ischemia), represents a truly unique ap

proach to the management of post-ischemic pathologic
conditions. and following ischemia associated with sur

gical procedures (e.g., by-pass surgery and transplanta
tion of organs). Since the trapping of endogenous free

ischemia or inflammation and demonstration in animals
emia.

Gerbil Stroke Model

An accepted animal model for determining the effect
of a compound on injury arising from a stroke is de
scribed by Chandler. et al.. J. Pharm. .Vfc’I/IOG'S l4.

137-146 (1985). Briefly. Mongolian gerbils are anesthe
tized with pentobarbital (40 mg/kg). A ventral midline
incision is made in the neck. Common carotids are ex

posed and separated from the vagosympathetic nerve
radicals is speci?c for only those cells that have been 35 trunk. A loop of unwaxed dental floss (Johnson and
exposed to the conditions that result in the production
Johnson) is placed around each carotid. The ends ofthe
of free radicals. the traps will have little or no effect on
floss are each passed through one of the lumens of a
normal cells. The bene?cial effects will occur only in
double
lumen catheter (Dural Plastics and Engineering.
injured cells. Moreover, because the bene?cial effect
Dural, NSW. Australia). The catheter and dental ?oss
does not require the presence of speci?c receptors or
are passed through the dorsal musculature and exited at
speci?c enzymes, the spin traps offer a signi?cant im
the dorsal surface of the neck. The catheter is ?xed in
provement in the treatment of ischemia/induced cellu
position, directly above the carotid artery. using cyano
lar dysfunction and necrosis.
In addition. these compounds should be extremely
acrylate adhesive at the exit site. The dental floss length
useful for the prophylactic treatment of chronic or
is marked in order to assure that the animal does not
periodic cytotoxic conditions that involve free radicals.

occlude the carotid during daily cleaning and explor

The CNS disease conditions that are expected to be

atory activity. The ventral incision is closed with 9 mm

treatable using such compounds include stroke, tran
sient ischemic attacks, Alzheimer necrosis, continued
cell loss in Parkinsonism, meningitis, cardiac resuscita
tion-induced brain damage, and damage arising as a

wound clips. After 48 hrs following instrumentation,

ischemia is produced by gently pulling the looped den

result oftrauma. especially head and spinal injuries with
associated bleeding from surrounding tissues into the

tal floss until the artery is occluded. Occlusion of the
artery is associated with loss of consciousness. ptosis
and a change in breathing pattern. Previous studies,

nervous tissues. It is expected that these compositions

using direct observation, have demonstrated that com

can also be used to treat a variety of other disorders 55 plete interruption of flow occurs under these condi

including damage resulting from exposure to high pres
sure oxygen or oxygen - enriched environments, espe

cially damage to the eyes resulting from placing very
premature babies on high oxygen respirators, drug and
/or alcohol abuse - induced damage to the CNS, as well 60

as other organs, and damage resulting from exposure to

ionizing radiation or photooxidation.
The PBN is preferably administered systemically,

tions. The occlusion is maintained for 10 minutes and
then the dental floss removed to allow complete reper
fusion. After reperfusion, the catheter is trimmed flush
with the surface of the neck.

'

The animals. male gerbils (50—6O gms). are purchased
from Tumblebrook Farm. West Brookfield. Mass. and
housed in groups of three for at least one week prior to

‘instrumentation. Following surgery, the gerbils are
most preferably intravenously, or orally, since this is the
most rapid and ef?cient means for directing the active 65 singly housed in order to avoid the possible accidental
induction of ischemia by cage mates. Food and water
compound to the site of free radical generation. How
ever. other methods of administration can be used, as

are available ad libitum in the home cage. All gerbils are

when PBN is administered intraperitoneally in the ex

maintained under a 12 hr light/dark cycle.

9

5,025,032

10

[.P. 1 hr prior to treatment. Gerbils are given an is
chemia/reperfusion treatment. or in the case of sham

EXAMPLE 1
Determination ofthe Extent of Peroxidation Damage in
Brain Tissue
Measurement of Tissue Damage by Free Radical
Generation

operated controls. placed in the animal holder but not
occlusion, for a de?ned period. The gerbils are killed by
decapitation. The brains are removed and placed on a
cooled stage within 2 min. The cortex of brain is iso
lated cold and stored at -—80° C. for about one week

Tissue damage can be measured as a function of the

until it is extracted. The cortex is homogenized at ice
temperature in a 0.5% NaCl solution (5 gm/ml) and the
homogenate is then extracted with 2:1 chloroform

generation of free radicals, protein carbonyl concentra
tion increase, and decrease in glutamine synthetase en

zymatic activity.

methanol mixture (v/v) to a final dilution of 20~fold the
volume of the tissue sample. The crude extract is

Free radicals are found in ischemia/reperfusion in

jured gerbil brains. There are several methods effective

washed thoroughly with 0.5% NaCl (5:1, v/v) and the
mixture is allowed to separate into two phases by stand
ing at 4° C. for 2 hr. The organic phase is recovered and

for measuring the generation of free radicals, including

spin trapping and salicylate hydroxylation. Salicylate
hydroxylation can be used to monitor hydroxyl free

bubbled with N3 to obtain a concentration that is needed

radicals in vivo. since hydroxylation products (2,5-and
2,3-dihydroxybenzoic acids, DHBA) are present in the
brains of gerbils pretreated with salicylate. The amount
of DHBA correlates closely with the amount of brain

or the solvent of the organic phase is evaporated to
dryness and the residue redissolved in chloroform. Fi
nally. the samples are transferred to a Pasteur pipette
20
(sealed at the capillary end) and bubbled with N3 for 5
injury observed in this model, as shown by Cao, et al.,
min. The pipettes are then placed in the sample cavity of
Neuroscience Le”. 88, 233-238 (1988). Oxidative dam
an IBM Bruker ESP3OO EPR spectrometer and scanned
age to gerbil brain proteins can be assessed by protein
for the presence of spin adducts. The usual spectrome
carbonyl group increase, which occurs as the ischemic
ter settings are as follows: Microwave power 19.8 m\\':
lesioned gerbil brain is allowed to reperfuse. Overall
tissue necrosis is also indicated by a decrease in the
modulation amplitude 0.975G. time constant 1310.72

enzymatic activity of glutamine synthetase (GS) in is

ms; scan range 100 G; and scan time 6 min. All spectra

chemic-lesioned gerbil brain. This decrease increases as
reperfusion time increases, such that at 60 min the GS

are recorded at room temperature. The coupling con

stants can be directly obtained from the instrument and

activity is decreased about 35% from normal values.
since since the instrument is controlled by an online
The enzymatic activity of GS is highly sensitive to 30 computer. simulated spectra of a mixture of spin
metal catalyzed oxidative damage. Therefore its loss
trapped free radicals can be compared with the bona
supports the notion that metal catalyzed oxidative dam
fide spectrum obtained in order to make prediction
age does occur in the reperfusion phase of the ischemic
regarding the trapped free radicals. An extensive data
lesioned gerbil brain. GS enzymatically converts gluta
base of spin coupling constants‘taken in different sol
mate to glutamine and thus a decrease in its activity may
vents using different systems is used for comparison
allow the buildup of glutamate, an excitatory toxic
purposes.
amino acid.
Spin-traps react with free radicals to form adducts.
Utilizing the ischemia/reperfusion lesioned brain of
the electron spin resonance (ESR) spectrum. which
gerbils. it was demonstrated that oxidative damage was
provides a mechanism to deduce the chemical identity
occurring. with the evidence as follows: (1) increased 40 of the free radicals trapped. The method used for in

levels of salicylate hydroxylation products. implicating

vivo spin trapping was developed by Dr. P. B. McCay

increased hydroxyl free radical flux in lesioned brain,

in combination with Dr. Ed Janzen. as reported by Lai.
et al., Arch. Biochem. Biop/zys. 2-14. 156-160 (1986). Free
radicals have been spin-trapped in ischemia/reperfusion
injury in rat heart by Bolli and McCay. J. C/i'n. Invest.

(2) increased levels of protein oxidation and a loss of

glutamine synthetase activity in lesioned brain, (3) free
radical formed from spin-traps in lesioned brains. (4)

45

spintrap mediated protection from brain ischemia/
reperfusion injury, and (5) an increased peroxidation
capacity of brain during the reperfusion phase after an
ischemic insult.
50

Demonstration of in Vivo Oxygen Free Radical Flux

by Spin-Trapping and HPLC with Electrochemical
Detection
Spin-trapping and HPLC with electrochemical de
tection (LCED) are used to quantitate hydroxylation

products of salicylate, formed in part by hydroxyl free

82, 476-485 (1988).
The production of free radicals during ischemia/
reperfusion induced injury in the gerbil brain was tested
using spin trapping. Both treated and control animals

- were administered the spin trap PBN (ct-phenyl-t-butyl

nitrone) before the experimental treatments. The data
demonstrate that large free radical signals were ob
tained from the extracts of brains of ischemia/reperfu
sion treated gerbils in contrast to very little signals from

sham-operated control animals. Surprisingly, the radi
cals are not what would be expected when a spin-trap
reacts with a free radical to produce a spin adduct. A

radical addition, and hydroxyl free radical adducts to
DNA and RNA. The extreme sensitivity of the LCED
six-line spectrum is expected from the spin-adduct of a
methodology, on the order of 103 to 104 gain over opti
cal methods. is a distinct advantage when attempting to 60 free radical of PBN. The six-line spectrum is due to the
free electron interacting with the spin % nuclear mag
ascertain the flux of oxygen free radicals in vivo. which
netic moment ofthe proton as well as the spin of 1 from
may only reach IO—° M under high oxidative stress
the nitrogen of the nitroxyl group. In contrast. these
conditions. It has been demonstrated in biochemical
spectra are only three lines. and are therefore due to the
systems that OH radicals could be trapped by salicylate
65 free electron interacting with the nitroxyl nitrogen
and quantitated using LCED.

only. which means that available protons are displaced

Electron spin resonance of brain lipid extract is mea
sured as follows. Gerbils are administered spin-trap

at a distance such that they are not influencing the free

dissolved in saline stored cold (protected from light)

electron.

11
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The most likely explanation for the results is that
PBN first traps a free radical, possibly a lipid carbon
free radical. after which the spin-adduct is then oxidized
to a nitrone which then traps another free radical, yield

ing a nitroxide having properties producing the ob
served spectra.

Two other spin-traps, DMPO (5,5-dimethylpyrro
line-N-oxide) and POBN (ot-pyridyl-l-oxide-N-t-butyl
nitrone), both of which have different chemical struc

12
EXAMPLE 2

Demonstration ofthe Protective Effect ofSpin-Traps in
Ischemia/Reperfusion Induced Brain Injury in Gerbils
The spin-trap PBN offers considerable protection to
the gerbil from brain injury brought on by an ischemia/
reperfusion insult and in addition helps prevent death
which often accompanies the brain injury. The data

tures from PBN, yielded nitroxide spectra (very similar, O demonstrating these statements are presented in FIGS.
1. 2. 3 and Table 1. Table 1 shows that animals given
3-lines, yet with slightly different nitrogen coupling

added to the extracts and it is then incubated for 24

PBN I.P.. dissolved in saline, at a dosage of 300 mg/kg,
60 min prior to 15 min ischemia, which is followed by
24 hr reperfusion, protected the animals from death.
that is, the animals lived for longer than 7 days, the time
point when lethality is evaluated. Ofthe control animals
which received saline. 50% of the yound and 100% of
the old gerbils had died as of the seventh day.

spin-trapped carbon free radicals, possibly lipid radi

chemia/reperfusion injury prevent the characteristic

constants and different intensities) as with PBN in the

ischemia/reperfusion treated gerbils. It is pertinent to
note that if the chloroform/methanol extract of brains

of animals which have been pretreated with PBN is
allowed to stand at room temperature for 24 hours, then

the 3-line signal decays. If, however, more PBN is then

Gerbils. which have received a brain ischemic insult
hours, trapped radial signals are observed in the extract
ofischemic/reperfusion animals. but signals are not seen 20 resulting in permanent injury. first exhibit a lethargic
reaction then a characteristic increase in spontaneous
in the sham-operated controls. Computer simulation of
locomotor activity above controls at 4 hours after isch
the signals developing show that three free radicals are
emia. The lesion-induced hyperactivity continues for
present. One has parameters equivalent to the three line
several days. Drugs that protect the animals from is
nitroxide observed previously and the other two are
cals. These observations indicate that oxidative events
were started in the ischemic brains but not in the sham
operated controls and these events are carried over, at

least in part. in the lipid extracts.

Demonstration of Ischemia/Reperfusion Induced
Increased Peroxidation Capacity of the Brain
Brain homogenate at ice temperature does not spon

taneously peroxidase. yet if the temperature is raised to
37° C. there is, in contrast to almost all other tissue
homogenates. spontaneous peroxidation. The rate of
peroxidation varies with brain region and is highly cor
related with the total iron content of the brain region.
Gerbil brain homogenate peroxidizes more rapidly than
rat brain. The susceptibility to peroxidation of brain

rise in spontaneous activity. PBN was effective at vari

ous dosages in protecting against ischemia/reperfusion
induced hyperactivity. as demonstrated by Table l and
FIG. 1. It can be seen that saline treated animals given
30 a 5 min ischemia insult had hyperactivity signi?cantly‘

higher than sham-operated controls 24 hr after isch
emia. However. animals which had received PBX~ at 32
or 100 mg/kg 1 hr prior to ischemia had no elevated
hyperactivity. PBN at 300 mg/kg caused a decreased

activity over controls. Data comparing activity at the
2-1 hr reperfusion time of sham-operated controls with 1
min ischemia. 5 min ischemia and 15 min ischemia le
sioned animals. which had received either saline or 300
mg/kg PBN. are shown in FIGS. 2. 3 and 4. The data
clearly demonstrate that the high dose of PBN caused a

homogenate after it has experienced an ischemia/reper

reduction in ischemia induced hyperactivity to levels of

fusion insult and the effect of time of reperfusion was
determined. The data were collected from 176 gerbils.
At every time point sham-operated animals were used

the control or lower.

as controls. The data show that after 10 min ofischemia
there is. if reperfusion is not allowed to occur. a de

crease in the rate of peroxidation. If reperfusion is al
lowed to occur after ischemia, then the rate of peroxida

tion increases significantly over sham-operated control.
animals in a time-course fashion. The increase is most

rapid in the first 60 min then slows, reaching a maxi
mum at 7 days following ischemia. after which it de
creases to values which were still higher than controls

at 14 days.
Brains from gerbils which have been pretreated with
pentobarbital and then given a 15 min ischemia period
followed by 15 min reperfusion have no increase in the
amount of spontaneous peroxidation above sham

operated controls. Thus not only does pentobarbital
protect gerbils from the damage brought about by is

TABLE 1
Histopatholngical Scores in Gr3l’bll\ 7 days after 5 min
of Global Cortical lschernia.

Group

Score

Control (no ischemia)

4.? (:5)

31 mg PEN/kg
100 mg PBX/kg‘
300 mg PBN/kg

2.5 (:7)
2.8 (:4)
i: iJi

‘N = b gerbils per group.

In order to obtain parameters relative to acute toxic

ity of PBN. total cumulative activity of normal gerbils
were investigated at a wide range of concentrations.
The data are shown in FIG. 5. Only at PBN concentra

tions of 1000 mg/kg and higher was there any alteration
in activity noted. PBN at 2000 mg/kg was not lethal to

animals. The one noted effect at high PBN concentra~
60 tions is an induced lethargic response which disappears

chemia/reperfusion injury. there is no increased peroxi
dation of the brain homogenate from pentobarbital

after 24 hours.

treated animals as compared with untreated animals.
Pre-treated animals lesioned by 15 min ischemia/l5 min

of animals given lethal strokes (15 min ischemia) is

homogenate peroxidation.

brain proteins. Gerbil brains which had received vari

‘

The effect of PBN administration on percent survival

shown in FIG. 6. 50% ofthe animals given 15 minutes
reperfusion had spontaneous brain homogenate peroxi 65 ischemia died. With pre-ischemic treatment with PBX.
dation about 15% above sham-operated controls. dem
100% of the animals survived.
onstrating a direct correlation between increased brain
Ischemia/reperfusion induced oxidative damage to

5,025,032
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ous treatments were analyzed for carbonyl groups on

effects of an ischemic insult to brain was tested. The

proteins. a measure of oxidative damage to protein. and
glutamine synthetase activity. The results are shown in
FIGS. 7 and 8 and compared in FIG. 9.
FIG. 7 shows oxidative damage to protein as mea

offer some protection, but DMPO was less effective
than POBN which was less effective than PBN.

results indicate that both DMPO and POBN appear to

Modifications and variations ofthe present invention.

sured by carbonyl content as a percentage of a control

compositions containing PBN and derivatives thereof,
and methods using the compositions for the treatment
of tissue damage resulting from ischemia or inflamma

gerbil brain given a ten minute ischemia at the indicated

time of reperfusion. 300 mg PBN/kg was administered
one hour prior to the onset of ischemia. Carbonyl pro
tein content was elevated above control levels in 10 min 10

ischemia treated brains without reperfusion.
Reperfusion for 15 min did'not enhance carbonyl

tion, will be obvious to those skilled in the art from the

foregoing detailed description. Such modifications and
variations are intended to come within the scope of the

following claims.

protein above the ischemia only values. After 60 min
reperfusion there was a signi?cant increase in carbonyl
proteinv PBN pretreatment prevented this rise.
FIG. 8 shows the oxidative damage to glutamine

We claim:
1. A method for in vivo treatment of oxidative CNS
tissue damage resulting from ischemia or in?ammation

synthetase activity as a percentage of a control gerbil
brain given a ten minute ischemia at the indicated time
of reperfusion. 300 mg PBN/kg was administered one
hour prior to the onset of ischemia. Glutamine synthe- _
tase (GS) activity was slightly lower than control val
ues after ischemia with no reperfusion. With increasing
reperfusion time, there was a dramatic loss in GS activ

comprising:
providing a-phenyl t-butyl nitrone and derivatives
thereof having spin trapping activity and prevent
ing ATP depletion in vivo in tissue and
a pharmaceutically acceptable carrier for delivery of
the ot-phenyl t-butyl nitrone to the CNS of a pa
tient.

ity such that after 60 min reperfusion, only 65% of the
2. The method of claim 1 wherein the phenyl butyl
activity remained. PBN pretreatment of the animals 25 nitrone derivatives are selected from the group consist
prevented this loss in G5 activity. Since this enzyme is
ing of hydroxy PBNs, PBN esters. acetoxy PBNs. alkyl

considered to be a glial cell marker, this data indicates
post ischemic damage also occurs in glial cellsv
FIG. 9 shows that there was a good correlation be
tween the loss of GS activity versus accumulation of

carbonyl protein when all of the samples analyzed are

compared.
Ischemia/Reperfusion Induced Gene Expression
T_he levels of mRNA for c-fos and c-jun were exam

ined in gerbil brain cortex after ischemia/reperfusion.
The results of 10 min ofischemia followed by 60 min of
reperfusion demonstrated that both c-fos and c-jun

PBNs, alkoxyl PBNs, phenyl PBNs.
3. The method of claim 1 wherein the PBN derivative
is functionalized to release in vivo a compound selected

from the group consisting of 2-. 3-. and 4-h_vdroxyphe-‘
nyl t-butyl nitrone; 2-. 3-. and 4-hydroxyphenyl t-but_vl
nitrone; 2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and
2-. 3-. and 4-aminophenyl t-butyl nitrone.
4. The method of claim 1 comprising as the active

ingredient ot-phenyl t-butyl nitrone.
5. The method of claim 1 further comprising adminis
tering an agent selected from the group consisting of

mRNA levels are elevated within 60 min after the in
streptokinase. tissue plasminogen activator. mannitol.
sult. Control animals and animals subjected to the sur 40 and lazaroids.
gery showed lower levels of c-fos mRNA was mark
6. The method ofclaim 1 wherein the PBX and deriv

edly enhanced. Pentobarbital pretreatment, which pro
tects the animals from ischemia/reperfusion injury,
prevented the induced expression of the c-fos gene,
whereas no pretreatment caused a large increase in c-fos
mRNA. PBN pretreatment suppresses the level of c-fos

induction in the ischemia/reperfusion injury.
Old gerbils are much more sensitive to‘ brain is

chemia/reperfusion injury than young animals, as
shown in Table 2. Data are expressed as number sur

viving/total tested.

an effective dosage to a patient to prevent reperfusion

injury of CNS tissue.
7. The method ofclaim 1 wherein the PBX and deriv

atives thereof is in a pharmaceutical carrier delivering
an effective dosage to a patient to prevent CNS tissue

damage from in?ammation.
8. The method of claim 1 wherein the PBN and deriv
atives thereof is provided in a dosage of 10 to 300 mg

PEN/kg body weight.
TABLE 2

Effects of PBN pretreatments on post reperfusion
lethulitv in voung adult gerbils (3-4 months of age).
Treatment
Age
(300 mg PBX/kg)
Saline
control

young

15/15

15/15

15 mm ischemia

young

10/10

5/10‘

retired

4/4

0/4

10 min ischemia

atives thereof is in a pharmaceutical carrier delivering

breeders; (18 mo.)
‘All \un'lvll'lg gerbils “ere \ubsequentl} tested for behtnitiral effects at 24 hr.

post-ischemia.

9. The method of claim 1 wherein the composition is
administered during or immediately after a stroke.
10. The method of claim 1 wherein the composition is
administered to a patient having a progressive neuronal
disorder.
11. The method of claim 1 wherein the composition is
administered to a patient exposed to high pressure oxy
60 gen or an oxygen enriched environment.

12. The method ofclaim 1 wherein the composition is
administered to a patient to mitigate damage to cells
EXAMPLE 3

Effectiveness of Spin-Trapping Reagents Other Than
PBN
In preliminary studies, the effectiveness of two other
spintraps, DMPO and POBN, in preventing the acute

from exposure to a chemical agent.

13. The method of claim 1 wherein the composition is

administered to a patient suffering from meningitis.
14. A composition for in vivo treatment of tissue
damage resulting from ischemia or inflammation not
associated with bacterial toxins comprising:

5,025,032
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a-phenyl t-butyl nitrone and derivatives thereof hav

ing spin trapping activity and preventing ATP
depletion in vivo in tissue of the formula:
0
H

ll

or

\

/

||

wherein W is C-CHg. NH-C-Z.

C=N+

/
X

\

0

Y

II

II

C-Cl-h. C-OZ. or Z: and

wherein:
Z is a C1 to C5 straight or branched alkyl group
further comprising a compound selected from

X is phenyl or

the group consisting of streptokinase. tissue plas
minogen activator. mannitol and lazaroides
a pharmaceutically acceptable carrier for intravenous

(ORln

administration to a patient,

wherein the a-phenyl nitrone is in an amount effec
tive to prevent tissue damage resulting from isch
emia or in?ammation not associated with bacterial

toxins wherein the nitrone and further compound

wherein R is H,

are present in effective amounts.

15. The composition of claim 14 wherein the phenyl
butvl nitrone derivatives are selected from the group

consisting of hydroxy PBNs‘ PBN esters. acetoxv
PBNs. alkyl PBNs. alkoxyl PBNs. phen_\'l PBNs.
16. The composition of claim 1 wherein the PBXY
derivative is functionalized to release in vivo a com

pound selected from the group consisting of 2-‘ 3-. and
and n is a whole integer from 1 to 5: or

4-hydroxyphenyl t-butyl nitrone: 2-. 3. and 4-h_vdrox
_vphenyl t-butyl nitrone: 2~. 3-. 3-. and 4-carboxyplienyl
t~butyl nitrone; and 2-. 3-. and 4-aminophenyl t-butyl
nitrone.

17. The composition of claim 14 comprising as the

active ingredient a-phen_vl t-but_vl nitrone.
18. The composition of claim 14 wherein the PBX
and derivatives thereof is in a pharmaceutical carrier
delivering an effective dosage to a patient to prevent

Y is a tert-butyl group that can be hydroxylated or

reperfusion injury.
*

acetylated on one or more positions; phenyl; or
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